# ACTengine® IMA203 Combined With mRNA-4203

> **NCT06946225** · PHASE1 · RECRUITING · sponsor: **Immatics US, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Cutaneous Melanoma
- Synovial Sarcoma

## Interventions

- **BIOLOGICAL:** IMA203
- **BIOLOGICAL:** mRNA-4203

## Key facts

- **NCT ID:** NCT06946225
- **Lead sponsor:** Immatics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946225, "ACTengine® IMA203 Combined With mRNA-4203". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06946225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*